macular degeneration
Ray Therapeutics Nets $4M CIRM Grant to Advance Geographic Atrophy Gene Therapy
The company wants to develop RTx-021 into a gene therapy that can deliver optogenetic proteins to patients' retinas as an office-based procedure.
Novartis Stops Developing Geographic Atrophy Gene Therapy Acquired From Syncona
Because of the decision, Syncona will write off $68.3 million in potential milestone payments that it was eligible for under a 2022 acquisition deal.
Sysmex Gets Approval in Japan for Retinal Dystrophy Gene Panel
The next-generation sequencing panel identifies genetic mutations that cause inherited retinal dystrophy, which results in vision problems, including blindness.
Complement Therapeutics Raises €72 Million in Series A Round
The company will use the funds to conduct a Phase Ib trial of its CTx001 gene therapy candidate in geographic atrophy patients.